A Novel Aminotetralin-Type Serotonin (5-HT) (2C) Receptor-Specific Agonist and 5-HT(2A) Competitive Antagonist/5-HT(2B) Inverse Agonist with Preclinical Efficacy for Psychoses

Development of 5-HT(2C) agonists for treatment of neuropsychiatric disorders, including psychoses, substance abuse, and obesity, has been fraught with difficulties, because the vast majority of reported 5-HT(2C) selective agonists also activate 5-HT(2A) and/or 5-HT(2B) receptors, potentially causing...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Canal, Clinton E., Morgan, Drake, Felsing, Daniel, Kondabolu, Krishnakanth, Rowland, Neil E., Robertson, Kimberly L., Sakhuja, Rajeev, Booth, Raymond G.
Médium: Artigo
Jazyk:Inglês
Vydáno: The American Society for Pharmacology and Experimental Therapeutics 2014
Témata:
Drug Discovery and Translational Medicine
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3989798/
https://ncbi.nlm.nih.gov/pubmed/24563531
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/jpet.113.212373
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky